Necessary to Evaluate and Justify Off-Label Use of Oncology Drugs to Provide Equal Access to Effective Treatment

Live Fagereng introduces a study on off-label use in oncology, which was presented at ESMO. In the Netherlands, 30% of all cancer treatments are off-label, with chemotherapy making up 60% of these treatments. Live Fagereng emphasizes the importance of integrating off-label treatment in cancer care, This is necessity to provide equal access to effective treatment for indications that may not be commercially viable for companies to pursue regulatory approvals due to small patient numbers or patent expiration.